Merrimack Pharmaceutical's MM-111 Granted Orphan Drug Status by FDA For Treatment of Advanced Gastric and Esophageal Cancers
"We are pleased that the
MM-111 is designed to inhibit ErbB3 (HER3) receptor signaling in cancers that overexpress ErbB2 (HER2). Overexpression of the ErbB2 cell surface receptor has been reported in 7-34 percent of gastric cancers according to various scientific articles. Research has shown that ErbB3 expression is associated with poor prognosis in gastric cancer and may contribute to resistance to some current standard treatments. Currently, MM-111 is being tested in a Phase 2 study in advanced gastric, esophageal and gastroesophageal junction cancers.
These two orphan drug designations will potentially provide
About
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development.
Forward-Looking Statement
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements in this press release include statements about the potential for MM-111 to provide clinical benefit and to achieve regulatory approval. Forward-looking statements involve substantial risks and uncertainties, and actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT: Media Contacts:Source:Dana Robie Merrimack 617-441-7408 drobie@merrimackpharma.comHeather Gitlitz Spectrum 202-587-2516 hgitlitz@spectrumscience.com
News Provided by Acquire Media